Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Recolony logo — Swiss start-up Recolony aims to develop an oral cancer medic...

Recolony

Swiss start-up Recolony aims to develop an oral cancer medication using bacteria.

Founded 2022 Switzerland Zurich, Switzerland 2-10 employees Grant Total: $160.00K Biotechnology

General Information

Company Name Recolony
Founded Year 2022
Location Switzerland Zurich, Switzerland +1
Employees 2-10
Industries Biotechnology
Funding Stage Grant
Social

Get notified when Recolony moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Recolony

Recolony is a Swiss biotech startup founded in 2022 with a promising goal - to develop a bacteria-based oral medication for treating and preventing cancer. Their flagship product, Recolony, offers a microbial solution specifically targeting colorectal cancer. This innovative approach holds tremendous potential in revolutionizing cancer treatment. The company recently secured a Fr.150.00K grant investment from Venture Kick on 21 February 2023, signifying a significant milestone for their progress and growth in the biotechnology industry. With their headquarters in Switzerland, Recolony is positioned among the notable players in the biotech sector, offering a unique and promising solution in the fight against cancer.

Taxonomy: Swiss start-up, Recolony, biotech, oral cancer, medication, bacteria-based, colorectal cancer, microbial solution, therapy, biotech start-up, cancer treatment, Switzerland, bacteria, prevention, treatment

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
21 Feb 2023
Grant •••••• 1
Investor
28 Apr 2022

Recolony Alternatives & Competitors

Recolony vs
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. United States

Harnessing the power of the immune system to develop treatments for cancer.

Unknown
23 employees
Biotechnology
Recolony vs
Sapphire Biotech
Sapphire Biotech

Pioneering advanced therapeutics and diagnostics to enhance global cancer care and ensure early dete...

11-50 employees
Biotechnology, Health Care
Recolony vs
Vaxon Biotech
Vaxon Biotech

Therapeutic vaccines empowering your immune system to target cancer without harming healthy cells, f...

3 employees
Biotechnology, Health Care
Also compare with: Recolony vs Boostimmune Boostimmune

FAQ About Recolony

Swiss start-up Recolony aims to develop an oral cancer medication using bacteria.
Recolony was founded in 2022.
Recolony is headquartered in Zurich, Switzerland.
Recolony operates in the following industries: Biotechnology.
Recolony has approximately 2-10 employees.
Recolony has completed 2 funding rounds, raising a total of $160.00K. The latest funding stage is Grant.
Top alternatives and competitors to Recolony include Tizona Therapeutics, Inc., Sapphire Biotech, Vaxon Biotech, Nouscom , CTMC - a joint venture between Resilience + MD Anderson Cancer Center. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Recolony and Tizona Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Recolony and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy